Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer

Abstract

Supplemental Digital Content is available in the text

Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials

“…chemotherapy should be combined use and with sufficient intensity, which is consistent with our findings. As found in our study, grade 3 or 4 vomiting and thrombocytopenia occurred more frequently in the polychemotherapy arm, and the incidence of urinary system toxicity tended to be higher, but the incidence of grade 3 and 4 toxicities was low overall and considered clinically acceptable, in accordance with previous studies [19][20][21]. As a systematic review affected by many factors, our study recommends polychemotherapy plus RT in the clinic, and some such regimens have indeed proven to have good efficacy.…”

Potentialities of multi-b-values diffusion-weighted imaging for predicting efficacy of concurrent chemoradiotherapy in cervical cancer patients

“…By adopting multi-b-values DWI, we can quantitatively measure therapeutic reaction non-invasively in vitro at ultra-early time-point with high accuracy. This may provide supplementary information for prompt and individualized interventions for poor responders to economize medical expenditure and alleviate unnecessary toxicity and complications [30] .…”

Concurrent chemoradiotherapy with paclitaxel and cisplatin for patients of locally advanced cervical squamous cell carcinoma: A single-arm phase II clinical study

“…The presently examined multi-drug regimen of TP in CCRT for LACC has previously been shown to yield superior outcomes relative to other DDP-based regimens [6]. The use of CCRT has increased the 5-y OS rate of patients with LACC significantly, by up to 6% [7].…”

“…Recently, some novel chemotherapeutic regimens based on DDP for CCRT appeared, such as DDP plus 5-FU, DDP plus gemcitabine and DDP plus paclitaxel (PTX), etc. CCRT with PTX plus DDP was reported to be the superior choice of concurrent chemotherapy regimen for LACC, concerning to its better 5-y disease-free survival rate and good tolerance [6].…”